The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A single arm, phase 2, multicenter, international trial of tisotumab vedotin (HuMax-TF-ADC) in previously treated, recurrent or metastatic cervical cancer.
 
Robert L. Coleman
Consulting or Advisory Role - Clovis Oncology; DOD-CDRMP; Esperance Pharmaceuticals; Genentech/Roche; NCCN
Research Funding - Abbott/AbbVie; Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Esperance Pharmaceuticals; Johnson & Johnson; Merck; OncoMed; Roche/Genentech
Travel, Accommodations, Expenses - Amgen; Array BioPharma; AstraZeneca/MedImmune; Bayer; Clovis Oncology; GOG Foundation; Merck; Millennium; New Mexico Cancer Center; Research to Practice; Roche/Genentech; University of California, Irvine; University of Cincinnati Cancer Center; University of Miami
 
Nicole Concin
Travel, Accommodations, Expenses - Amgen; Roche
 
Thomas J. Herzog
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Johnson & Johnson; Roche/Genentech; Tesaro
 
Linn Lena Woelber
Honoraria - GlaxoSmithKline; Jenapharm; Medac; MSD; Roche; Tesaro
Consulting or Advisory Role - Tesaro
Research Funding - Medac; Roche
 
Mansoor Raza Mirza
Leadership - Karyopharm Therapeutics; SeraCare
Stock and Other Ownership Interests - Karyopharm Therapeutics; SeraCare
Honoraria - Advaxis; AstraZeneca; Cerulean Pharma; Clovis Oncology; Novocure; Pfizer; Roche; tesaro
Consulting or Advisory Role - AstraZeneca; Cerulean Pharma; Clovis Oncology; Genmab; Karyopharm Therapeutics; Novocure; Pfizer; Tesaro
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Pfizer (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Karyopharm Therapeutics; Pfizer; Roche; SeraCare; Tesaro
 
Bradley J. Monk
Leadership - US Oncology
Honoraria - Abbvie; Advaxis; Amgen; AstraZeneca; Bayer; Biodesix; Cerulean Pharma; Clovis Oncology; GlaxoSmithKline; Gradalis; Immunogen; Incyte; Insys Therapeutics; Janssen; Mateon Therapeutics; Merck; Myriad Pharmaceuticals; Nucana; Oxigene; Oxigene; Perthera; Pfizer; Precision Oncology; Roche/Genentech; Tesaro; Verastem; Vermillion
Consulting or Advisory Role - Abbvie; Advaxis; Amgen; AstraZeneca; Bayer; Biodesix; Cerulean Pharma; Clovis Oncology; GlaxoSmithKline; Gradalis; Immunogen; Incyte; Insys Therapeutics; Mateon Therapeutics; Merck; Myriad Pharmaceuticals; Nucana; Oxigene; Perthera; Pfizer; Precision Oncology; Roche/Genentech; Tesaro; Verastem; Vermillion
Speakers' Bureau - AstraZeneca; Clovis Oncology; Janssen; Roche/Genentech; Tesaro
Research Funding - Advaxis (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Genentech (Inst); Immunogen (Inst); Janssen (Inst); Lilly (Inst); Morphotek (Inst); Novartis (Inst); Nucana (Inst); Pfizer (Inst); Regeneron (Inst); Tesaro (Inst)
 
David Cibula
No Relationships to Disclose
 
Domenica Lorusso
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Roche; Tesaro
Research Funding - Clovis Oncology; PharmaMar
 
Antonio González-Martín
Consulting or Advisory Role - AstraZeneca; PharmaMar; Roche; Tesaro
Speakers' Bureau - AstraZeneca; PharmaMar; Roche; Tesaro
Travel, Accommodations, Expenses - AstraZeneca; PharmaMar; Roche; Tesaro
 
Kristian Windfeld
Employment - Genmab; Lundbeck
Stock and Other Ownership Interests - Genmab; Janssen; Lundbeck; Novo Nordisk
 
Jeroen Lammerts van Bueren
Employment - Genmab
Stock and Other Ownership Interests - Genmab
Patents, Royalties, Other Intellectual Property - Genmab
 
Signe Diness Vindeloev
Employment - Genmab
Stock and Other Ownership Interests - Genmab
 
Reshma A. Rangwala
Employment - Genmab; Merck
Stock and Other Ownership Interests - Merck
 
Ignace Vergote
Consulting or Advisory Role - Amgen (Inst); Array Biopharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); GE Healthcare (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Intuitive Surgical (Inst); Janssen-Cilag (Inst); Lilly (Inst); MedImmune (Inst); Menarini (Inst); Merck Sharp & Dohme (Inst); Morphotek (Inst); Nektar (Inst); Novo Nordisk (Inst); Oasmia Pharmaceutical AB (Inst); PharmaMar (Inst); Phillips Gilmore Oncology (Inst); Roche (Inst); Sanofi (Inst); Schering-Plough (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Fresenius Biotech (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Janssen-Cilag (Inst); Karyopharm Therapeutics (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Merrimack (Inst); Morphotek (Inst); Nektar (Inst); Nerviano Medical Sciences (Inst); Novartis (Inst); Pfizer (Inst); Quintiles (Inst); Roche (Inst); Sandoz (Inst); Sanofi (Inst); Schering-Plough (Inst); Tesaro (Inst); Vifor Pharma (Inst); Wyeth (Inst)
Travel, Accommodations, Expenses - AstraZeneca; GCI Health; Oasmia Pharmaceutical AB; PharmaMar; Roche